BCMA-Targeted CAR T-Cell Therapies in Multiple Myeloma

ISB 1442, which received orphan drug designation from the FDA, is currently under investigation in a first-in-human phase 1/2 trial as a treatment for patients with relapsed/refractory multiple myeloma.

Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.

An expert panel highlights novel therapeutic approaches for newly diagnosed and relapsed multiple myeloma.

CancerNetwork®’s podcast dives into an article focused on treatment options for older, transplant-ineligible patients with multiple myeloma.

Experts from the Mayo Clinic and Moffitt Cancer Center go head-to-head to discuss recent data in multiple myeloma and updates from recent meetings.

Rahul Banerjee, MD, FACP, discusses a recent presentation from the Tandem meeting regarding BCMA CAR T-cell therapy in patients with multiple myeloma.